<DOC>
	<DOCNO>NCT02467361</DOCNO>
	<brief_summary>This open label , multi-center , Phase 1/2 study BBI608 administer combination immunotherapy adult patient advance cancer . The goal study determine RP2D BBI608 combination immunotherapeutic agent .</brief_summary>
	<brief_title>A Study BBI608 Administered Combination With Immune Checkpoint Inhibitors Adult Patients With Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) local regulatory requirement 2 . A histologically cytologically confirm cancer metastatic , unresectable , recurrent treatment ipilimumab , nivolumab , pembrolizumab reasonable therapeutic option opinion investigator . 3 . ≥ 18 year age 4 . Measurable disease define ImmuneRelated Response Evaluation Criteria Solid Tumors ( irRECIST ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 6 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last dose 7 . Females childbearing potential must negative serum pregnancy test 8 . Aspartate transaminase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) alanine transaminase ( ALT ) ≤ 2.5 × upper limit normal ( ULN ) . 9 . Hemoglobin ( Hgb ) ≥ 9 g/dl 10 . Total bilirubin ≤ 1.5 × ULN . Patients liver lesion hepatocellular carcinoma total bilirubin &lt; 2.0 x ULN may eligible agreed upon investigator medical monitor sponsor . 11 . Creatinine ≤ 1.5 × ULN , patient creatinine level institutional upper limit normal , creatinine clearance must &gt; 60 mL/min/1.73 m^2 . 12 . Absolute neutrophil count ≥ 1.5 x 10^9/L 13 . Platelets ≥ 100 x 10^9/L ; patient hepatocellular carcinoma may enroll provided platelet count ≥ 75 x 10^9/L . 14 . Life expectancy ≥ 3 month Exclusion criterion : 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose BBI608 . Patients may begin BBI608 date determine investigator medical monitor sponsor minimum 7 day since last receiving anticancer treatment , provide treatmentrelated adverse event ( AEs ) resolve deem irreversible 2 . Had surgical procedure require general anesthesia inpatient hospitalization recovery le 4 week prior begin protocol therapy . 3 . Any known , untreated , brain metastasis . Treated subject must stable 4 week completion treatment brain metastasis image document stability require . Patients must clinical symptom brain metastasis require systemic corticosteroid &gt; 10 mg/day prednisone equivalent least 2 week prior first dose study drug . 4 . Pregnant breastfeed 5 . Unable unwilling swallow BBI608 capsule daily 6 . Significant gastrointestinal disorder ( ) ( e.g. , active Crohn 's disease ulcerative colitis , history extensive gastric resection and/or small intestinal resection ) absorption oral medication impair . 7 . Has active autoimmune disease require immunosuppression exception subject isolate vitiligo , resolve childhood asthma atopic dermatitis , control hypoadrenalism hypopituitarism , euthyroid patient history Grave 's disease . 8 . Has interstitial lung disease active , noninfectious pneumonitis 9 . Has transplant organ undergone allogeneic bone marrow transplant 10 . Has receive live vaccine within 30 day prior first dose . 11 . Known hypersensitivity component protocol therapy 12 . Uncontrolled concurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement 13 . Subjects history another primary cancer , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) localize prostate cancer require systemic therapy ; c ) primary tumor know active disease present , opinion investigator medical monitor sponsor , affect patient outcome set current diagnosis . 14 . Abnormal ECGs clinically significant QT prolongation ( QTc &gt; 480 msec ) , clinically significant cardiac enlargement hypertrophy , new bundle branch block exist leave bundle branch block , sign new , active ischemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
</DOC>